Evogene Ltd. Files 6-K for H1 2025 Results
Ticker: EVGN · Form: 6-K · Filed: Sep 30, 2025 · CIK: 1574565
Sentiment: neutral
Topics: financial-results, sec-filing, foreign-private-issuer
TL;DR
Evogene dropped its H1 2025 results on 9/30. Check the 6-K.
AI Summary
Evogene Ltd. filed a Form 6-K on September 30, 2025, reporting its results of operations for the six months ended June 30, 2025. The filing is for a foreign private issuer and is being submitted to the SEC.
Why It Matters
This filing provides investors with an update on Evogene's financial performance for the first half of 2025, which is crucial for understanding the company's operational status and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) and does not contain new material events or significant financial changes.
Key Players & Entities
- Evogene Ltd. (company) — Registrant
- Securities and Exchange Commission (company) — Recipient of filing
- June 30, 2025 (date) — End of reporting period
- September 2025 (date) — Month of report
- September 30, 2025 (date) — Filing date
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report Evogene Ltd.'s results of operations for the six months ended June 30, 2025, as required for foreign private issuers.
What period does the financial information in this filing cover?
The financial information covers the six months ended June 30, 2025.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on September 30, 2025.
Is Evogene Ltd. required to file annual reports under Form 20-F or Form 40-F?
Yes, Evogene Ltd. indicates it files annual reports under Form 20-F.
What is Evogene Ltd.'s principal executive office address?
Evogene Ltd.'s principal executive office is located at 13 Gad Feinstein Street, Park Rehovot, Rehovot, 7638517, Israel.
Filing Stats: 403 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2025-09-30 07:00:53
Filing Documents
- zk2533800.htm (6-K) — 14KB
- exhibit_99-1.htm (EX-99.1) — 1203KB
- exhibit_99-2.htm (EX-99.2) — 68KB
- 0001178913-25-003427.txt ( ) — 7054KB
- evgn-20250630.xsd (EX-101.SCH) — 139KB
- evgn-20250630_cal.xml (EX-101.CAL) — 67KB
- evgn-20250630_def.xml (EX-101.DEF) — 174KB
- evgn-20250630_lab.xml (EX-101.LAB) — 1231KB
- evgn-20250630_pre.xml (EX-101.PRE) — 301KB
- zk2533800_htm.xml (XML) — 1196KB
From the Filing
Evogene Ltd. - 1574565 - 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission File Number: 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street Park Rehovot , Rehovot 7638517 , Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS Results of Operations- Six Months Ended June 30, 2025 This Report of Foreign Private Issuer on Form 6-K, or Form 6-K, is being furnished by Evogene Ltd., or Evogene, to the Securities and Exchange Commission, or SEC, for the sole purposes of: (i) furnishing, as Exhibit 99.1 to this Form 6-K, unaudited condensed consolidated financial statements of Evogene as of and for the six-month period ended June 30, 2025; and (ii) furnishing, as Exhibit 99.2 to this Form 6-K, Evogene's Operating and Financial Review and Prospects, which discusses and analyzes Evogene's financial condition and results of operations as of, and for the six-month period ended, June 30, 2025 . The contents of Exhibits 99.1 and 99.2 to this Form 6-K are incorporated by reference in the registration statements on Form F-3 (SEC File No. 333-277565) and Form S-8 (SEC File Nos. 333-193788, 333-201443, 333-203856, 333-259215 and 333-286197) of Evogene, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. EXHIBIT INDEX Exhibit No. Description 99.1 Unaudited Condensed Consolidated Financial Statements for the Six Months Ended June 30, 2025. 99.2 Operating and Financial Review and Prospects for the six-month period ended June 30, 2025. 101 Interactive data files pursuant to Rule 405 of Regulation S-T: (i) Consolidated Interim Statements of Financial Position, (ii) Consolidated Interim Statements of Profit or Loss, (iii) Consolidated Interim Statements of Changes in Equity; (iv) Consolidated Interim Statements of Cash Flows, and (v) Notes to Interim Consolidated Financial Statements. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: September 30, 2025 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer